Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01074632 · ClinicalTrials.gov registry record · Phase 1

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

A Phase 1 study, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target

NCT01074632: Completed Phase 1 study, sponsored by Sumitomo Pharma America.

NCT01074632 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01074632, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target

Study Summary

The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

Interventions

  • DRUG Lurasidone HCl

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2009-05
Est. Completion 2009-09
Phase Phase 1
Sumitomo Pharma America

168 total trials

What the finished NCT01074632 record still lists

NCT01074632 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).

The record links to 0 conditions, and to 1 intervention - of which Lurasidone HCl is the first listed.

NCT01074632 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01074632 about?

NCT01074632 is a clinical study titled "Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl". The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

What is the current status of trial NCT01074632?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2009-05. Estimated completion is 2009-09.

What interventions are being tested in trial NCT01074632?

The interventions under investigation include: Lurasidone HCl (DRUG).

Who is sponsoring clinical trial NCT01074632?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01074632's enrollment target sits among peer trials

26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01074632, the US trial registry maintained by the National Library of Medicine. NCT01074632 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.